These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30219823)

  • 21. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
    ; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
    Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telmisartan to reduce cardiovascular risk in older HIV-infected adults: a pilot study.
    Lake JE; Seang S; Kelesidis T; Liao DH; Hodis HN; Stein JH; Currier JS
    HIV Clin Trials; 2015 Oct; 16(5):197-206. PubMed ID: 26360501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial.
    Aberg JA; Sponseller CA; Ward DJ; Kryzhanovski VA; Campbell SE; Thompson MA
    Lancet HIV; 2017 Jul; 4(7):e284-e294. PubMed ID: 28416195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of standard dose multivitamin supplementation on disease progression in HIV-infected adults initiating HAART: a randomized double blind placebo-controlled trial in Uganda.
    Guwatudde D; Wang M; Ezeamama AE; Bagenda D; Kyeyune R; Wamani H; Manabe YC; Fawzi WW
    BMC Infect Dis; 2015 Aug; 15():348. PubMed ID: 26285704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
    Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Purdon S;
    HIV Med; 2001 Jan; 2(1):27-34. PubMed ID: 11737373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.
    Lo J; Lu MT; Ihenachor EJ; Wei J; Looby SE; Fitch KV; Oh J; Zimmerman CO; Hwang J; Abbara S; Plutzky J; Robbins G; Tawakol A; Hoffmann U; Grinspoon SK
    Lancet HIV; 2015 Feb; 2(2):e52-63. PubMed ID: 26424461
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pentoxifylline, inflammation, and endothelial function in HIV-infected persons: a randomized, placebo-controlled trial.
    Gupta SK; Mi D; Dubé MP; Saha CK; Johnson RM; Stein JH; Clauss MA; Mather KJ; Desta Z; Liu Z
    PLoS One; 2013; 8(4):e60852. PubMed ID: 23593327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.
    Saag MS; Cahn P; Raffi F; Wolff M; Pearce D; Molina JM; Powderly W; Shaw AL; Mondou E; Hinkle J; Borroto-Esoda K; Quinn JB; Barry DW; Rousseau F;
    JAMA; 2004 Jul; 292(2):180-9. PubMed ID: 15249567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial.
    ADVICE study group
    Lancet HIV; 2018 Oct; 5(10):e553-e559. PubMed ID: 30257802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-blind placebo-controlled pilot trial of acemannan in advanced human immunodeficiency virus disease.
    Montaner JS; Gill J; Singer J; Raboud J; Arseneau R; McLean BD; Schechter MT; Ruedy J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jun; 12(2):153-7. PubMed ID: 8680886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can Probiotics Reduce Inflammation and Enhance Gut Immune Health in People Living with HIV: Study Designs for the Probiotic Visbiome for Inflammation and Translocation (PROOV IT) Pilot Trials.
    Kim CJ; Walmsley SL; Raboud JM; Kovacs C; Coburn B; Rousseau R; Reinhard R; Rosenes R; Kaul R
    HIV Clin Trials; 2016 Jul; 17(4):147-57. PubMed ID: 27267710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
    Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
    AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection.
    Zanni MV; Toribio M; Robbins GK; Burdo TH; Lu MT; Ishai AE; Feldpausch MN; Martin A; Melbourne K; Triant VA; Suchindran S; Lee H; Hoffmann U; Williams KC; Tawakol A; Grinspoon SK
    JAMA Cardiol; 2016 Jul; 1(4):474-80. PubMed ID: 27438325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
    Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
    JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial.
    ENCORE1 Study Group
    Lancet; 2014 Apr; 383(9927):1474-1482. PubMed ID: 24522178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.